ME.NO.PAUSE.
EstroG-100¢ç
EstroG-100¢ç(¹é¼ö¿À µî º¹ÇÕÃßÃâ¹°)Àº ¹é¼ö¿À, ÇѼӴÜ, ´ç±Í¸¦ ¹èÇÕÇÑ ±¹³» ÃÖÃÊ ½Ä¾àó ¿©¼º °»³â±â ±â´É¼º ÀÎÁ¤ ¿ø·áÀÔ´Ï´Ù.
´Ù¼öÀÇ ÀÎüÀû¿ë½ÃÇè ¹× ¿¬±¸³í¹®À» ÅëÇØ 10°¡Áö °»³â±â Áõ»ó °³¼± È¿°ú¸¦ È®ÀÎÇÏ¿´À¸¸ç
ƯÈ÷ ¿¡½ºÆ®·Î°Õ ¼öÄ¡(E2, FSH)¿¡ ¿µÇâÀÌ ¾ø°í, ¿¡½ºÆ®·Î°Õ ¼ö¿ëü¿¡ °áÇÕÇÏÁö ¾Ê¾Æ ¿©¼º ÁúȯÀ¸·ÎºÎÅÍ ¾ÈÀüÇÏ°Ô ¼·ÃëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¹Ì±¹ FDA ±â´É¼º ¹°Áú(NDI) ÀÎÁõ, ij³ª´Ù ½Ä¾àû õ¿¬•±â´É¼º ¹°Áú(NPN) ¶óÀ̼±½º ȹµæ, À¯·´½ÄÇ°¾ÈÀüû ³ëºíǪµå Åë°ú µîÀ» ÅëÇØ
Àü ¼¼°èÀûÀ¸·Î ¸¹Àº Áß³â ¹× ³ë³â±â ¿©¼ºµéÀÇ »ç¶ûÀ» ¹Þ°í ÀÖ½À´Ï´Ù.
Exclusivity
±Û·Î¹ú ƯÇã ȹµæ ÇöȲ
ƯÇã ¸íĪ: Æó°æ±â Áõ»óÀÇ ¿¹¹æ ¶Ç´Â Ä¡·á¿ë ½Ä¹°¼º ¿¡½ºÆ®·Î°Õ Á¶¼º¹°
(Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause)
(Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause)
±¹°¡ | µî·Ï¹øÈ£ | ±¹°¡ | µî·Ï¹øÈ£ |
---|---|---|---|
´ëÇѹα¹ | 10-1141194 | À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, Æú¶õµå) | 2370072 |
¹Ì±¹ | 9,433,595 | ||
ij³ª´Ù | 2745020 | ¸ß½ÃÄÚ | 328059 |
·¯½Ã¾Æ | 2491926 | ¸»·¹ÀÌ½Ã¾Æ | MY-184493-A |
Áß±¹ | ZL200880132506.0 | Àεµ³×½Ã¾Æ | ID.P.000050866 |
È£ÁÖ | 2008365666 | ºê¶óÁú | PI0823391-8 |
Approval
±¹°¡ | ÀÎÇã°¡¸í |
---|---|
¹Ì±¹ | New Dietary Ingredient |
ij³ª´Ù | Natural Health Product |
À¯·´ | Novel Food Ingredient |
ÀϺ» | ½Ä¾à±¸ºÐÁ¶È¸ |
¸»·¹ÀÌ½Ã¾Æ | Food Supplement, Traditional Medicine |
Çʸ®ÇÉ | Herbal Medicine |
Àεµ | Food for Special Dietary Use |
À̶õ | Natural Product |
ÀÌÁýÆ® | Herbal Medicine Product |
Mechanism of Action
¿¡½ºÆ®·Î°Õ È°¼ºÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë ¾øÀÌ ¾ÈÀüÇÏ°Ô 10°¡Áö °»³â±â Áõ»ó °³¼±
No adverse event at all subjects
No change in weight, BMI and liver enzymes
No change in serum E2 & FSH
No influence on estrogen-sensitive tissues
No binding affinities for ER¥á, ER¥â, and nonselective ER
No toxic effects shown in toxicity studies
No change in weight, BMI and liver enzymes
No change in serum E2 & FSH
No influence on estrogen-sensitive tissues
No binding affinities for ER¥á, ER¥â, and nonselective ER
No toxic effects shown in toxicity studies
5 Human clinical studies published
KMI(Kupperman menopause index, °»³â±âÁö¼ö) 62% °³¼±
10°¡Áö °»³â±â Áõ»ó °³¼±(¾È¸éÈ«Á¶ ¹× ¹ßÇÑ, ¼Õ¹ßÀú¸², ºÒ¸éÁõ, ½Å°æÁú, ¿ì¿ïÁõ, ¾îÁö·³Áõ, ÇǷΰ¨, °üÀý ¹× ±ÙÀ°Åë, ÀÇÁÖ°¨, Áú °ÇÁ¶)¡Ø Phytother. Res. 2012, 26:510-6.
40~70¼¼ ¿©¼º 60¸í ´ë»ó 12ÁÖ ¼·Ãë
EstroG-100¢ç ¼·Ãë ¸¸Á·µµ
°»³â±â Áõ»ó °³¼± Àü¹ÝÀû ¸¸Á·µµ 100%J Midlife Health. 2023, 14:285-290.EstroG-100¢ç ¼·Ãë ¸¸Á·µµ
Numerous in vitro & in vivo studies
¾È¸éÈ«Á¶
- Tail skin temperature (TST) ¡é
°ñ´Ù°øÁõ
- Femoral bone mineral density ¡è
ºÒ¸éÁõ
- Sleep induction time ¡é
- Sleep continuity time ¡è
- Recovery time ¡é
- Melatonin in plasma & GABA in brain ¡è
¿ì¿ïÁõ
- Behavior evaluation ¡è
- Serotonin & dopamine in brain¡è
- Corticosterone in serum ¡è
°üÀý¿°
- Edema rate¡é
- Cartilage maintenance factors (Col2¥á1, Aggrecan, Proteoglycan, SOX-9, Collagen I, Collage X) ¡è
- Cartilage destruction factors (TIMP-1, MMP3, MMP7) ¡é
- Degenerative osteoarthritis inducing factors (COX-2, MMP, NF-¥êB, TNF-¥á, IL-1¥â) ¡é
ÇÇ·Î
- Glycogen content in muscle ¡è
- LDH activity in muscle ¡é
- Genetic expression of exercise fatigue recovery factors (PPAR-¥ä, UCP-3) ¡è
- Antioxidant enzyme activity (SOD, CAT, GST) ¡è
- Antioxidant compounds in liver (GSH) ¡è
- Oxidative stress marker in liver (MDA) ¡é
Recommended dosage
175 ~ 514 mg/day